Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings

Core Insights - Omega Therapeutics is a clinical-stage biotechnology company focused on developing programmable epigenomic mRNA medicines to treat a wide range of diseases [3] - The company will present new preclinical data at three upcoming scientific meetings, showcasing the capabilities of its OMEGA platform [2] Upcoming Presentations - Omega will present a poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on the controlled epigenetic upregulation of CXCL9 and CXCL10 in hepatocellular carcinoma [2] - At the 12th International mRNA Health Conference, Omega will present on programmable epigenomic mRNA therapeutics for tuning α-globin, targeting treatments for β- and α-thalassemia [2] - A poster will also be presented at the American Association for the Study of Liver Diseases' Annual Meeting regarding the durable upregulation of P1-isoform Hepatocyte Nuclear Factor 4 alpha (HNF4α) [2] Company Overview - Founded in 2017, Omega Therapeutics aims to revolutionize genomic medicine through its innovative approach to pre-transcriptionally modulating gene expression [3] - The company’s pipeline includes therapeutic candidates targeting oncology, regenerative medicine, and multigenic diseases, including inflammatory and cardiometabolic conditions [3]